(Q37789144)

23 August 2017

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins (English)

1 reference

23 August 2017

1 reference

2

M Bemark

1 reference

23 August 2017

1

N Lycke

1 reference

23 August 2017

15 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

3

1 reference

23 August 2017

6

1 reference

23 August 2017

556-566

1 reference

https://scigraph.springernature.com/pub.10.1038/mi.2010.54

23 August 2017

0 references

cites work

Immunological memory and protective immunity: understanding their relation

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Duration of humoral immunity to common viral and vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Mechanism of action of clinically approved adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Vaccine adjuvants: the dream becomes real

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Generating memory with vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Memory B cells: effectors of long-lived immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Maturation of the immune response in germinal centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

In vivo imaging of germinal centres reveals a dynamic open structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Germinal-center organization and cellular dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Lineage specification and heterogeneity of T follicular helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Dysregulation of germinal centres in autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Human IgM+CD27+ B cells: memory B cells or "memory" B cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Multiple layers of B cell memory with different effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

B cell receptor signal strength determines B cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

T cell-independent IgA class switch recombination is restricted to the GALT and occurs prior to manifest germinal center formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Gut-associated lymphoid tissue contains the molecular machinery to support T-cell-dependent and T-cell-independent class switch recombination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Dependence of germinal center B cells on expression of CD21/CD35 for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Cytokine-secreting follicular T cells shape the antibody repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

A critical role for IL-21 in regulating immunoglobulin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

A fundamental role for interleukin-21 in the generation of T follicular helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Requirement of B cells for generating CD4+ T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Duration of antiviral immunity after smallpox vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Maintenance of the plasma cell pool is independent of memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Long-lived plasma cells: a mechanism for maintaining persistent antibody production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Effect of CpG oligonucleotides on vaccine-induced B cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Antigen presentation to naive CD4 T cells in the lymph node.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Dendritic cells: understanding immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Modulation of adaptive immunity with Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Modulating the immune response with dendritic cells and their growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Differential antigen processing by dendritic cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Development, trafficking, and function of memory T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The role of chemokine receptors in primary, effector, and memory immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Natural versus adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Immune regulation in tumor-bearing hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Vaccines against myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Targeted vaccine adjuvants based on modified cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Germinal center reutilization by newly activated B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Intestinal Bacteria Trigger T Cell-Independent Immunoglobulin A2 Class Switching by Inducing Epithelial-Cell Secretion of the Cytokine APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

CD40 ligand-transduced co-stimulation of T cells in the development of helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

https://api.crossref.org/works/10.1038%2FMI.2010.54

1 reference

7 January 2021

Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Cholera Toxin Promotes the Induction of Regulatory T Cells Specific for Bystander Antigens by Modulating Dendritic Cell Activation

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Cholera toxin adjuvant greatly promotes antigen priming of T cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2010.54

7 January 2021

Identifiers

DOI

10.1038/MI.2010.54

1 reference

23 August 2017

1 reference

PubMed ID

20844480